KRAS and non-small cell lung carcinoma: In particular, for 25 tumors treated with erlotinib, LogitDA achieved a prediction accuracy of 0.76, and its prediction accuracy increased to 0.85 if we focused on the 20 EGFR and KRAS wild-type patients with NSCLC; LogitDA correctly predicted all 12 resistant tumors and five of eight tumors sensitive to erlotinib(Supplementary Table S2B).